Divalproex and Olanzapine Indications and Monitoring

Indications for Divalproex

The American Academy of Child and Adolescent Psychiatry recommends Divalproex as a first-line treatment option for acute manic or mixed episodes in bipolar I disorder, with response rates of 53% in children and adolescents 1, 2
The American Psychiatric Association recommends Divalproex for preventing relapse of mood episodes, with treatment continuing for at least 12-24 months after stabilization 1, 2, 3
Divalproex is effective when combined with atypical antipsychotics for severe presentations or treatment-resistant cases 1, 4
Valproate demonstrates particular effectiveness compared to lithium in mixed or dysphoric mania 1
Valproate is considered a preferred option in patients with rapid cycling patterns 1
Divalproex is particularly effective for managing irritability, agitation, and aggressive behaviors in bipolar disorder 1
The American Academy of Neurology recommends valproate for migraine prevention 5
The American Academy of Neurology recommends valproate for epilepsy, though it should be avoided if possible in women of childbearing age due to teratogenic risks 3

The American Academy of Child and Adolescent Psychiatry recommends baseline assessment of liver function tests, complete blood count with platelets, and pregnancy test in females before starting Divalproex 1, 2
The American Psychiatric Association recommends ongoing monitoring of serum drug levels, hepatic function, and hematological indices every 3-6 months for patients taking Divalproex 1, 3
The American College of Obstetricians and Gynecologists recommends avoiding Divalproex in women of childbearing age when possible due to teratogenic risks and association with polycystic ovary disease 1, 3
The American Heart Association recommends baseline metabolic assessment, including BMI, waist circumference, blood pressure, fasting glucose, and fasting lipid panel, for patients starting Olanzapine 1, 2
The American Diabetes Association recommends follow-up monitoring of BMI, blood pressure, fasting glucose, and lipids at 3 months then annually for patients taking Olanzapine 1, 2

The American Psychiatric Association recommends that both medications require 6-8 weeks at therapeutic doses before concluding ineffectiveness 1
The American Academy of Child and Adolescent Psychiatry recommends maintenance therapy to continue for at least 12-24 months after stabilization to prevent relapse 1, 2, 3
The American Psychiatric Association recommends never using antidepressants without a mood stabilizer in bipolar disorder, as this can trigger mania or rapid cycling 1, 2, 4